NCT04623541 2026-04-13
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
Clinical Trials
35 trialsNCT06564038 2026-04-13
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT04542824 2026-04-08
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT06353386 2026-03-24
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04300556 2026-03-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06568094 2025-12-31
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT06689163 2025-09-03
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT07124936 2025-08-15
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT05201248 2025-01-07
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Active not recruiting
NCT03677141 2024-12-18
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT04060394 2024-10-10
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Laekna Limited
Phase 1/2 Completed
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02348216 2024-06-04
ZUMA-1
Gilead Sciences
Phase 1/2 Completed
NCT05405439 2023-11-03
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT01234025 2023-10-06
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Ionis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01485861 2023-09-14
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Genentech, Inc.
Phase 1/2 Completed
NCT01992653 2023-03-14
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Genentech, Inc.
Phase 1/2 Completed
NCT02596971 2021-05-24
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02055820 2020-06-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Hoffmann-La Roche
Phase 1/2 Completed
NCT02344017 2019-12-19
DUALIDES
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01666314 2018-03-20
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT02072863 2017-05-02
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Completed
NCT01511536 2016-07-28
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Sanofi
Phase 1/2 Completed
NCT00514267 2015-08-13
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Astellas Pharma Inc
Phase 1/2 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00770848 2014-03-10
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Amgen
Phase 1/2 Completed
NCT00137436 2011-08-29
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Pfizer
Phase 1/2 Completed